Fierce Biotech

Pfizer sues Metsera over Novo's shock counteroffer, but obesity biotech stands firm

For Novo, it marks the boldest move yet for recently appointed CEO Maziar Mike Doustdar. In response to a slowdown in sales ...

Is It Time to Dump Your Shares of Pfizer?

Pfizer also has set its sights on becoming a giant in oncology, and to support this, completed the acquisition of Seagen in ...
pharmaphorum

Pfizer files another lawsuit against Metsera, Novo Nordisk

After filing one lawsuit to try to block Novo Nordisk's $9 billion effort to trump the takeover, Pfizer has returned to the ...

Pfizer (PFE) Q3 Earnings: What To Expect

Global pharmaceutical company Pfizer (NYSE:PFE) will be announcing earnings results this Tuesday before market open. Here’s what you need to know.

Pfizer Reports Earnings Tuesday. Management Has Big Questions to Answer.

The 11th-hour attempt by Novo to snatch away Metsera, which Pfizer had agreed to buy in September, has upended debate around ...

Pfizer Q3 Earnings Preview: Results to test recovery hopes amid TrumpRx deal, Metsera dispute

Pfizer ( PFE) is set to report its Q3 earnings on Tuesday, November 4, before the market opens. Wall Street expects earnings of $0.64 per share, down 39.6% year-over-year, on revenue of $16.52 billion ...

1 Incredible Reason to Buy Pfizer Stock (PFE) in November

Pfizer has long been a solid dividend payer, having raised its dividend annually for 16 years. Its yield is high because the ...